Gumede, Siphamandla B. http://orcid.org/0000-0002-7870-1363
Wensing, Annemarie M. J.
Lalla-Edward, Samanta T.
de Wit, John B. F.
Francois Venter, W. D.
Tempelman, Hugo A.
Hermans, Lucas E.
Funding for this research was provided by:
Carnegie Corporation of New York (G-19-57145)
The Swedish International Development Cooperation Agency (54100113)
Uppsala Monitoring Centre and the DELTAS Africa Initiative (107768/Z/15/Z)
National Heart, Lung, and Blood Institute (UG3HL156388)
University of the Witwatersrand
Article History
Accepted: 2 June 2023
First Online: 29 June 2023
Declarations
:
: AMJW reports grants or contracts from an Investigator-initiated grant from Gilead global for the study of HIV Integrase resistance (Rosetta) (pending, grant to institution), Health Holland ICD-ICK4HIVCure (paid to institution), and ZonMW (Dutch government, paid to institution); consulting fees from Gilead, ViiV/GSK, and Janssen (paid to institution); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Virology Education and the Southern African HIV Clinicians Society (paid to institution). AMJW Serves as a CEO for the European Society for Antiviral Research (ESAR) (unpaid), as governing Board member European AIDS Clinical Society, Chair of the European AIDS conference 2021 (unpaid, travel expenses paid to Institution), Member of the WHO Resnet (unpaid, travel expenses paid to Institution), Chair of the IAS-USA HIV drug resistance panel (unpaid), and as an Organizing Committee member of the European HIV and Hepatitis Meeting (unpaid, travel expenses paid to Institution). WDFV received funding for the ADVANCE RCT through his institution from UNITAID, USAID, and SAMRC, and received study drug from ViiV Healthcare and Gilead Sciences. WDFV also reports funding for his unit from the Bill and Melinda Gates, Foundation, National Institutes for Health, UNITAID, Foundation for Innovative New Diagnostics (FIND) and the Children’s Investment Fund Foundation (CIFF), and received drug donations from Merck and J&J Sciences for investigator-led clinical studies. The unit leads investigator-led studies that receive financial support from Merck and ViiV and is involved in commercial drug studies for Merck. The unit performs evaluations of diagnostic devices for multiple biotech companies. WDFV. Also receives honoraria for educational talks and advisory board membership for Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J, Sanofi and Virology Education; participates on DSMB for NIH International; is currently an unpaid board member for Dira Sengwe and was an unpaid board member for SAHCS. None of the ADVANCE RCT funders were involved in the design, execution, or analysis of this study. All other authors report no potential conflicts.
: Ethics approval for the ITREMA trial was obtained from the University of Pretoria Human Research Ethics Committee (Ref Number: 69/2015) and the Department of Health, Limpopo province (Ref No 4/2/2). Ethical clearance for this sub-study was obtained from the University of the Witwatersrand Human Research Ethics Committee (M190641), and approval was provided by the Johannesburg Health District (DRC Ref: 2019-10-005, National Health Research Database Reference Number: GP_201910_031).
: Not applicable.
: Not applicable.